Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal (Revised)

by Zacks Equity Research • January 21, 2022 • 0 Comments

Sanofi’s (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.